Fundraising Fox
GT Metabolic Solutions
Saint Michael, US · Founded 2020 · 2 known investors
Find your way into GT Metabolic Solutions
Sign up to see every warm intro you have to GT Metabolic Solutions
- Paths you didn't know you had: your email and LinkedIn already hold routes to the GT Metabolic Solutions team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GT Metabolic develops magnetic compression anastomosis technology, including its MagDI System, which uses magnets to create incisionless, sutureless duodeno-ileal anastomoses during bariatric surgery. The technique is intended to support weight loss and glycemic control in obese patients with or without type 2 diabetes, and its products have received FDA marketing authorization and clearances.
Founders & leadership
TT
Thierry ThaureChief Executive OfficerThaure joined the company in 2020 after leading Cephea Valve Technologies as chief executive, a role he held through 2024. His background is in running medical device companies through development and commercialization.
MG
Michel GagnerCMO & Co-founderGagner is a bariatric and general surgeon who founded Clinique Michel Gagner, MD, Inc. in 2010 and serves as chief of surgery at Westmount Square Surgical Center, with earlier posts as chief of laparoscopic and bariatric surgery at Weill Cornell Medical College, chief of laparoscopic surgery at Mount Sinai Medical Center, and chairman of surgery at Mount Sinai Medical Center Miami Beach. He previously co-founded EndoMetabolic Solutions, where he was vice-president from 2007 to 2011.
Investors · 2
Reported raises · per SEC filings
Form D private placements$46.5M disclosed across 3 rounds · 2022–2023
▶$23.2MraisedDec 2025 · 201 investors · OtherRule 506(b)
▶$23.2MraisedDec 2025 · 201 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Thierry ThaureExecutive Officer, Director
- Michel GagnerExecutive Officer, Director
- Offering amount
- $25.4M
- Amount sold
- $23.2M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$4.7MraisedNov 2023 · 31 investors · OtherRule 506(b)
▶$4.7MraisedNov 2023 · 31 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michel GagnerExecutive Officer, Director
- Thierry ThaureExecutive Officer, Director
- Offering amount
- $25.4M
- Amount sold
- $4.7M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$18.6MraisedJan 2023 · 88 investors · OtherRule 506(b)
▶$18.6MraisedJan 2023 · 88 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michel GagnerExecutive Officer, Director
- Thierry ThaureExecutive Officer, Director
- Offering amount
- $20.2M
- Amount sold
- $18.6M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does GT Metabolic Solutions do?
- GT Metabolic develops magnetic compression anastomosis technology, including its MagDI System, which uses magnets to create incisionless, sutureless duodeno-ileal anastomoses during bariatric surgery. The technique is intended to support weight loss and glycemic control in obese patients with or without type 2 diabetes, and its products have received FDA marketing authorization and clearances.
- Who are GT Metabolic Solutions's investors?
- GT Metabolic Solutions's investors include Healthtech Capital, Krillion Ventures.
- How much funding has GT Metabolic Solutions raised?
- GT Metabolic Solutions has disclosed $46.5M raised across 3 rounds.
- Where is GT Metabolic Solutions headquartered?
- GT Metabolic Solutions is headquartered in Saint Michael, US.